Mixed implantation of different kinds of self-expending metal stents for femoropopliteal arteriosclerosis obliterans：biocompatibility and limb salvage rate
Chen Bin
Liu Jun-jun
Zhao Zong-gang
Li Jun
Li Yong-xin
Xin Hai
Liu Bing
Wang Hao-fu
Abstract：BACKGROUND:Stent implantation has become the main treatment method of Trans-Atlantic Inter-Society Consensus II (TASCII) C and D’s femoropopliteal lesions, but the lesions are always too long that we have to implant mixed stents to overlap the arteries. OBJECTIVE:To evaluate the up to mid term safety and efficacy of different self-expending metal stents for treatment of femoropopliteal arteriosclerosis obliterans. METHODS:Thirty patients with long-segmental femoropopliteal arteriosclerosis obliterans (40 affected limbs) were enroled, including 34 males and 5 females, aged 44-87 years old. Each affected limb was implanted with one LifeStent with another one or two different kinds of stents. After 39 months of folow-up, the successful stenting rate, post-implantation biocompatibility, limb salvage rate, primary and secondary patency rate were evaluated. RESULTS AND CONCLUSION: Totaly 93 stents were implanted in the 40 affected limbs, including 27 affected limbs with 2 stents and 13 affected limbs with 3 stents. There were 40 LifeStent stents, 45 Luminexx stents, 1 Smart stent, 2 Aurora stents, 2 Pulsar18 stents, and 3 Invatec stents, with a successful stenting rate of 92%. The limb salvage rate at 12 months was 95%. A 24 months after surgery, the primary and secondary patency rates
<br> were (42.0±0.1)% and (59.0±3.7)%, respectively. There was no severe complication and inhospital mortality. These findings suggest that the mixed implantation of self-expending stent implantation (LifeStent mixed with other kinds of stents) for femoropopliteal arteriosclerosis obliterans appears to be safe and efficient during the up to mid term.
Keywords：Subject headings：StentsPopliteal ArteryArterial Occlusive Diseases
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 1233-1238 )